MDMA for PTSD Under FDA Review; GLP-1 for Opioid Cravings; ADHD an Evolutionary Aid?

The FDA is currently reviewing midomafetamine capsules — an MDMA-containing therapeutic — as a potential post-traumatic stress disorder treatment to be used in combination with psychological intervention based on the phase III MAPP1 and MAPP2 studies, Lykos Therapeutics announced.

Is the DEA making the ADHD medication shortage worse? (CBS News)

The GLP-1 medication liraglutide (Victoza, Saxenda) helped reduce opioid cravings, according to a small study of 20 people with opioid use disorder. (STAT)

Areas of greater racial and ethnic diversity had significantly fewer buprenorphine prescribing clinicians, with 45% to 55% fewer prescribers in urban areas and 62% to 79% fewer prescribers in rural areas as minority composition increased. (Journal of Addiction Medicine)

Hormone replacement therapy significantly improved symptoms of depression in menopausal women when used either alone or as adjunct to antidepressants. (Menopause)

Was ADHD an evolutionary advantage while foraging? (Proceedings of the Royal Society B: Biological Sciences)

A CDC study found that 6.4% of adults living alone reported feelings of depression — higher than the 4.1% of those living with others.

Can antidepressants used during pregnancy affect offspring’s brain development? A mouse study may provide clues. (Nature Communications)

Sleep signatures were altered after effective deep brain stimulation for depression. (Translational Psychiatry)

More scientists and physicians are turning their attention to eating disorders in men. (New York Times)

That being said, males with anorexia had a 6-fold higher mortality rate compared with males in the general population. (CMAJ)

Odor cues like the smell of ground coffee or tobacco ash evoked memories for people with depression; could they help with their therapy? (JAMA Network Open)

Please enable JavaScript to view the

comments powered by Disqus.